Skip to main content

Paul S. St. Marie


[email protected]



Paul focuses his practice on patent counseling and litigation with an emphasis on Hatch-Waxman Act matters involving pharmaceutical patents. He has experience in all stages of litigation, including managing discovery, taking and defending depositions, motion practice, and drafting settlement agreements. Paul has represented clients in IP matters in US district courts, the Federal Circuit, the Patent Trial and Appeal Board, the Trademark Trial and Appeal Board, and the International Trade Commission.

Prior to joining Mintz, Paul was an associate at a New York–based law firm, where he represented generic pharmaceutical companies in Hatch-Waxman litigation across multiple jurisdictions. He also practiced at a boutique trial law firm, where he represented clients in a broad spectrum of litigation involving commercial disputes, probate issues, trademark infringement, real estate contracts, family law matters, and workers’ compensation. Earlier, while working as an associate in the Intellectual Property Litigation Group of a global law firm, Paul handled intellectual property litigation in US district courts, the Federal Circuit, the PTAB, the TTAB, and the ITC.

While earning his JD, Paul served as a judicial extern for the Honorable Leonard P. Stark of the US District Court for the District of Delaware and interned for the Honorable Peter G. Sheridan of the US District Court for the District of New Jersey. In law school, he served as a staff editor of the Rutgers University Law Review and a legal writing teaching assistant and also participated in Rutgers Law’s Intellectual Property Law Clinic. In addition, Paul received a first year legal writing award and participated in the American Intellectual Property Law Association’s Giles S. Rich Memorial Intellectual Property Moot Court Competition.

* Not admitted to practice in New York. Admitted to practice only in the State of New Jersey.

News & Press

Press Release Thumbnail

A Mintz team led by Richard Gervase, Member and Chair of the firm’s Royalty & Revenue Interest Financing Transactions Group, advised global investment firm Sixth Street in a non-dilutive, senior secured credit facility of up to $475 million for Apellis Pharmaceuticals. Apellis received $375 million in funding at close, with ability to access an additional $100 million under the facility at the Company’s option prior to September 2025, subject to the satisfaction of certain conditions.

Read less